Observations on the CATIE Schizophrenia StudyHow Should the Data Be Translated Into Clinical Practice?

A supplement to Clinical Psychiatry News and supported by Pfizer, Inc.
A panel of experts met in November 2005 in Washington, DC, to discuss the first published results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. Participants included several principal study investigators as well as experts in the treatment and management of schizophrenia and bipolar illness. The content of this supplement is based in part on that discussion.

•Faculty
•Topics

Peter F. Buckley, MD
Medical College of Georgia
School of Medicine
Grant/Research Support: Astra/Zeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceutica, LP, Pfizer Inc., and Solvay Pharmaceuticals, Inc. Consultant/Received Honoraria: Abbott Laboratories, Alamo Pharmaceuticals, LLC, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer.

Joseph P. McEvoy, MD
Duke University
Medical Center
Clinical Grant Support: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer Inc. Consultant: GlaxoSmithKline, Eli Lilly, and Pfizer.

Topics

• Design
• Overview of Results
• Dosing
• Metabolics
• Clinical Implications of CATIE Phase I
• Beyond Phase I
• Implications of CATIE Beyond Schizophrenia
• Conclusion

A supplement to Clinical Psychiatry News and supported by Pfizer, Inc.
A panel of experts met in November 2005 in Washington, DC, to discuss the first published results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. Participants included several principal study investigators as well as experts in the treatment and management of schizophrenia and bipolar illness. The content of this supplement is based in part on that discussion.

•Faculty
•Topics

Peter F. Buckley, MD
Medical College of Georgia
School of Medicine
Grant/Research Support: Astra/Zeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceutica, LP, Pfizer Inc., and Solvay Pharmaceuticals, Inc. Consultant/Received Honoraria: Abbott Laboratories, Alamo Pharmaceuticals, LLC, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer.

Joseph P. McEvoy, MD
Duke University
Medical Center
Clinical Grant Support: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer Inc. Consultant: GlaxoSmithKline, Eli Lilly, and Pfizer.

Topics

• Design
• Overview of Results
• Dosing
• Metabolics
• Clinical Implications of CATIE Phase I
• Beyond Phase I
• Implications of CATIE Beyond Schizophrenia
• Conclusion

A supplement to Clinical Psychiatry News and supported by Pfizer, Inc.
A panel of experts met in November 2005 in Washington, DC, to discuss the first published results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study. Participants included several principal study investigators as well as experts in the treatment and management of schizophrenia and bipolar illness. The content of this supplement is based in part on that discussion.

•Faculty
•Topics

Peter F. Buckley, MD
Medical College of Georgia
School of Medicine
Grant/Research Support: Astra/Zeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceutica, LP, Pfizer Inc., and Solvay Pharmaceuticals, Inc. Consultant/Received Honoraria: Abbott Laboratories, Alamo Pharmaceuticals, LLC, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer.

Joseph P. McEvoy, MD
Duke University
Medical Center
Clinical Grant Support: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, and Pfizer Inc. Consultant: GlaxoSmithKline, Eli Lilly, and Pfizer.

Topics

• Design
• Overview of Results
• Dosing
• Metabolics
• Clinical Implications of CATIE Phase I
• Beyond Phase I
• Implications of CATIE Beyond Schizophrenia
• Conclusion